Business Wire

ABB Robotics to Develop Solutions for the Hospital of the Future

Share

ABB announced that it will introduce collaborative robots to medical laboratories as it opens a new healthcare hub at the Texas Medical Center (TMC) innovation campus in Houston, Texas.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190709005953/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Advanced collaborative robotics for medical laboratories and hospitals (Photo: Business Wire)

The facility will be ABB’s first dedicated healthcare research center when it opens in October 2019. ABB’s research team will work on the TMC campus with medical staff, scientists and engineers to develop non-surgical medical robotics systems, including logistics and next-generation automated laboratory technologies.

Sami Atiya, President of ABB’s Robotics and Discrete Automation business said, “The next-generation laboratory processes developed in Houston will speed manual medical laboratory processes, reducing and eliminating bottlenecks in laboratory work and enhancing safety and consistency. This is especially applicable for new high-tech treatments, such as the cancer therapies pioneered at the Texas Medical Center, which today require manual and time-consuming test processes.”

Today, a limiting factor to the number of patients who can be treated is the need for highly skilled medical experts who spend a large part of their day doing repetitive and low value tasks, such as preparing slides and loading centrifuges. Using robots to automate these tasks will enable medical professionals to focus on more highly skilled and productive work, while ultimately helping more people to receive treatment through dramatically speeding the testing process.

ABB has analyzed a wide range of current manual medical laboratory processes and estimates that 50% more tests could be carried out every year using automation, while training robots to undertake repetitive processes will reduce the need for people to do tasks which cause repetitive strain injury (RSI).

As the world population ages, countries are spending an increasingly larger proportion of their GDP on healthcare. In addition to improving the quality of patient care, increasing healthcare efficiency through automation can ease some of the societal, political and financial challenges that this will cause. The market for non-surgical medical robots is estimated to reach nearly 60,000 by 2025 with the market almost quadrupling vs. 2018, according to an internal ABB research.

ABB’s collaborative robots, which already operate in food and beverage laboratories worldwide, are well suited to medical facilities as they don’t require safety fences to operate safely and efficiently alongside people. The robots will undertake a range of repetitive, delicate and time-consuming activities including dosing, mixing and pipetting tasks as well as sterile instrument kitting and centrifuge loading and unloading.

Houston is a focal point for medical technology research globally and the TMC innovation ecosystem is the ideal location for ABB’s new healthcare hub. A 20-strong team from ABB Robotics will work in the new 5,300 sq ft (500m2) research facility, which includes an automation laboratory and robot training facilities, as well as meeting spaces for co-developing solutions with innovation partners.

“With this exciting partnership, Texas Medical Center continues to push the boundaries of innovative collaboration with cutting-edge industry partners by establishing TMC as the epicenter for ABB Robotics’ entry into the healthcare space,” said Bill McKeon, President & CEO of Texas Medical Center. “Operating a city within a city that sees 10 million patients on an annual basis, it is essential to prioritize efficiency, and precision and to develop processes that are easily repeatable in nature. By bringing ABB into the fold at TMC Innovation with this first-of-its-kind R&D facility for creating robotics solutions in healthcare, TMC is emphasizing its commitment to doing just that.”

“We are proud to co-develop collaborative robotics systems for the Hospital of the Future with one of the world’s most advanced partners and to test them in real-world laboratories to ensure they add value to healthcare professionals, driving innovation and transforming how medical laboratories operate worldwide,” added Atiya. “A key element of ABB’s long-term growth strategy is to continue to invest and innovate in service robotics, bringing our automation expertise to new areas such as healthcare and building on our automotive and electronics sectors business.”

ABB (ABBN: SIX Swiss Ex) is a pioneering technology leader with a comprehensive offering for digital industries. With a history of innovation spanning more than 130 years, ABB is today a leader in digital industries with four customer-focused, globally leading businesses: Electrification, Industrial Automation, Motion, and Robotics & Discrete Automation, supported by its common ABB Ability™ digital platform. ABB’s market‑leading Power Grids business will be divested to Hitachi in 2020. ABB operates in more than 100 countries with about 147,000 employees.

ABB Robotics is a pioneer in industrial and collaborative robots and advanced digital services. As one of the world’s leading robotics suppliers, we are active in 53 countries and over 100 locations and have shipped over 400,000 robot solutions for a diverse range of industries and applications. We help our customers to improve flexibility, efficiency, safety and reliability, while moving towards the connected and collaborative factory of the future. www.abb.com/robotics

About TMC INNOVATION: Texas Medical Center (TMC)—the largest medical city in the world—is at the forefront of advancing life sciences. Home to the brightest minds in medicine, TMC nurtures cross-institutional collaboration, creativity, and innovation among its 106,000-plus employees. With a campus of more than 50 million square feet, TMC annually hosts 10 million patients, performs over 180,000 surgeries, conducts over 750,000 ER visits, performs close to 14,000 heart surgeries, and delivers over 25,000 babies. Beyond patient care, TMC is pushing the boundaries of clinical research across its extensive network of partner institutions on a daily basis, pioneering effective health policy solutions to address the complex health care issues of today, and cultivating cutting-edge digital health applications and medical devices. For more information, please visit www.tmc.edu.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

ABB Ltd
Affolternstrasse 44
8050 Zurich
Switzerland

Media Relations
Phone: +41 43 317 71 11
Email: media.relations@ch.abb.com

Investor Relations
Phone: +41 43 317 71 11
Email: investor.relations@ch.abb.com

TMC Media Contacts:
Public Content
+1 713 524 2800
Mark Sullivan / Jonathan Babin
mark@public-content.com / jonathan@public-content.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 Data for Incyte’s Retifanlimab (Zynyz ® ) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet13.6.2025 01:45:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) in adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal cancer (SCAC) who have not been previously treated with systemic chemotherapy, were published in The Lancet.1 “The publication of the POD1UM-303/InterAACT 2 trial in The Lancet is a testament to the strength of the data generated for retifanlimab in patients with inoperable locally recurrent or metastatic SCAC, a disease which until recently had seen limited innovation for decades,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “SCAC can be a devastating disease, and patients often have a poor prognosis. These data supported the U.S. Food and Drug Administration (FDA) approval of Zynyz® (retifanl

Güntner Drives Group-Wide Innovation in 2024 Sustainability Report12.6.2025 22:30:00 EEST | Press release

Güntner, a global leader in refrigeration and heat exchange technology, today announced its featured role in the newly released 2024 A-HEAT Sustainability Report. The report outlines significant progress toward ambitious environmental goals—fueled by Güntner’s commitment to measurable, innovation-led sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612897493/en/ Güntner advances global sustainability goals with progress in natural refrigerants, water savings, and circular economy efforts. Working toward its 2030 sustainability targets, Güntner delivered significant achievements across key areas including natural refrigeration integration, water and energy efficiency and the development of circular economy solutions. These efforts reflect Güntner’s ongoing mission to make sustainability not just a goal, but a core driver of innovation. Key milestones include a near-complete transition to natural refrigerants

Windsurf Launches First GPU Cluster in Germany, Expanding Secure Enterprise AI in Europe12.6.2025 21:45:00 EEST | Press release

Windsurf, a leader in AI-powered software development, today announced its first GPU cluster in Germany, as product demand surges and the company expands performance capacity across the EU. With over 100 local enterprise customers already using Windsurf products, the new cluster marks the company’s first major international step in building scalable infrastructure for the European market. Located in Frankfurt, home to some of the world’s strictest data security laws, the cluster was a natural choice for Windsurf’s first deployment. This cluster was specifically designed to meet the unique security and performance requirements of European enterprises, providing a framework for high performance in even the most complex, secure environments. “With about 6 million developers across Europe, users deserve infrastructure that meets them where they are,” said Varun Mohan, CEO of Windsurf. “The demand for secure AI-powered development is undeniable and by launching this GPU cluster, we aim to b

Xsolla Partners With Defold to Enable Seamless In-game Purchases for Web Developers12.6.2025 20:00:00 EEST | Press release

Xsolla, a leading global video game commerce company, announces a new strategic partnership with Defold, the cross-platform game engine trusted by professionals and indie developers worldwide. This collaboration introduces a seamless integration between Xsolla and Defold-built web games on CrazyGames, enabling developers to easily monetize their titles just in time for the CrazyGames x Defold Game Jam running June 13–15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612569206/en/ (Graphic: Xsolla) To address the complexity of in-game monetization, Xsolla and Defold have developed a new SDK that allows Defold developers to implement in-game purchasing functionality without the complex manual API setup required. With Xsolla’s sponsorship and support, this integration removes friction from the monetization journey, allowing developers to focus on building engaging games, not commerce infrastructure. This SDK connects three

Pioneering Cancer Plasticity Atlas will Help Predict Response to Cancer Therapies12.6.2025 18:00:00 EEST | Press release

The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich today announced a collaboration to build the foundation of a single cell atlas, focused on understanding and elucidating cancer plasticity in response to therapies. The collaboration will catalyze an ambitious future phase to develop a cancer plasticity atlas encompassing hundreds of millions of cells. Utilizing novel organoid perturbation and Artificial Intelligence (AI) platforms, the aim is to create a comprehensive dataset to fuel foundational drug discovery models and cancer research. Dr. Mathew Garnett, Group Leader at the Sanger Institute, and Prof. Fabian Theis, Director of the Computational Health Center at Helmholtz Munich and Associate Faculty at the Sanger Institute, will be the principal investigators in the collaboration. Garnett’s research team has generated novel 3D organoid cultures that serve as highly scalable and functional cancer models with the ability to capt

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye